RAPT

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 12, 2024
Letter, Atopic dermatitis, Telephone, RAPT, News, Asthma, P.C, Therapy, FDA, Food

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT) on behalf of RAPT stockholders.

Key Points: 
  • NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT) on behalf of RAPT stockholders.
  • Our investigation concerns whether RAPT has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • The company expects to receive a formal clinical hold letter from the FDA.”
    On this news, the Company’s stock price declined.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Retrieved on: 
Thursday, March 7, 2024
Pomerantz, RAPT, FDA, Prior, Atopic dermatitis, Food, News, Letter, Liver failure, Therapy, LLP

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).
  • The investigation concerns whether RAPT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
SAN, Research, RAPT, Atopic dermatitis, Asthma, AACR, Inflammation, Consultant, Safety, Therapy, Patient, Cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023.
  • Separately, our Phase 2 study of tivumecirnon in cancer is ongoing and we will be presenting an update at AACR in April.”
    Financial Results for the Fourth Quarter and the Year Ended December 31, 2023
    Fourth Quarter Ended December 31, 2023
    Net loss for the fourth quarter of 2023 was $30.9 million, compared to $23.0 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $26.8 million, compared to $19.5 million for the same period in 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $6.5 million, compared to $5.0 million for the same period in 2022.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, RAPT, FDA, Prior, Atopic dermatitis, Food, News, Letter, Liver failure, Therapy, LLP

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).
  • The investigation concerns whether RAPT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

Retrieved on: 
Wednesday, February 21, 2024
FDA, LLP, Atopic dermatitis, News, Therapy, Government, Letter, RAPT, Private investigator

RADNOR, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT) (“RAPT”).

Key Points: 
  • RADNOR, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT) (“RAPT”).
  • If you are a RAPT investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP : Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.
  • For more information about Kessler Topaz Meltzer & Check, LLP , please visit www.ktmc.com .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Retrieved on: 
Wednesday, February 21, 2024
Pomerantz, RAPT, FDA, News, Atopic dermatitis, Food, Letter, Liver failure, Therapy, LLP

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).

Key Points: 
  • NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT).
  • The investigation concerns whether RAPT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC

Retrieved on: 
Tuesday, February 20, 2024
RAPT, FDA, News, Atopic dermatitis, Food, Asthma, Fraud, Letter, ISS, Therapy, Pharmaceutical industry

ATLANTA, Feb. 20, 2024 (GLOBE NEWSWIRE) --  Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) complied with federal securities laws.

Key Points: 
  • ATLANTA, Feb. 20, 2024 (GLOBE NEWSWIRE) --  Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) complied with federal securities laws.
  • If you purchased RAPT Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq.
  • Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Retrieved on: 
Tuesday, February 20, 2024
Liver, SAN, Drug allergy, Autoimmune disease, RAPT, FDA, Atopic dermatitis, Food, Asthma, COVID-19, Inflammation, Letter, Liver failure, Safety, History, Therapy, Patient, Q&A, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from the FDA. The clinical hold determination was based on a serious adverse event of liver failure in one patient in the atopic dermatitis trial, the cause of which is currently unknown but which has been characterized as potentially related to zelnecirnon. Dosing of zelnecirnon has been halted in both clinical trials, as has enrollment of new trial participants. The clinical hold does not apply to RAPT’s ongoing trial of tivumecirnon (FLX475) in oncology.

Key Points: 
  • The company expects to receive a formal clinical hold letter from the FDA.
  • Dosing of zelnecirnon has been halted in both clinical trials, as has enrollment of new trial participants.
  • The clinical hold does not apply to RAPT’s ongoing trial of tivumecirnon (FLX475) in oncology.
  • The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Monday, February 26, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Atopic dermatitis, Food, Liver failure, News, Therapy, Letter, RAPT

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT).
  • Investors who purchased RAPT securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RAPT .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Retrieved on: 
Tuesday, February 13, 2024
SAN, Pharmacy, RAPT, Drug development, MBA, Hypoxia, Inflammation, Doctor of Philosophy, University, Therapy, Business, Patient, Astex Pharmaceuticals, CMC, Pharmaceutical industry

“I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.

Key Points: 
  • “I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.
  • Nipun brings over 27 years of extensive biopharmaceutical and drug development experience specializing in successful product development and commercial manufacturing.
  • Nipun holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School of Business.
  • Nipun added, "I am pleased to join the RAPT leadership team during this exciting period.